Livazo

Selected form

Pitavastatin

Treatment option: Hyperlipidemia, Dyslipidemia, Lipid Profile, Myopathy

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Livazo

Livazo is a prescription medicine containing the active ingredient Pitavastatin (Pitavastatin calcium), which is used to manage high levels of cholesterol and other lipids in the blood. It belongs to the drug class known as statins.

Property	Description
Active ingredient	Pitavastatin (Pitavastatin calcium)
Form	Film-coated tablet
Pharmacological class	HMG-CoA reductase inhibitor (Statin)
Common use	Management of high cholesterol/mixed dyslipidemia
Origin	Fully synthetic

What Type of Medicine is Livazo? (Identity and Classification)

Livazo is fundamentally a fully synthetic chemical compound classified as an HMG-CoA reductase inhibitor, which is the formal name for the statin class of lipid-lowering agents. The medication is presented as a single-component product in the form of a film-coated tablet designed for oral administration. Pitavastatin is recognized for its high potency at low doses compared to many other statins. A key differentiating feature is its distinct metabolic pathway: it primarily clears from the body via glucuronidation, with minimal reliance on the Cytochrome P450 (CYP) 3A4 enzyme. This characteristic is considered a significant factor in clinical practice, as it potentially reduces the risk of drug-drug interactions for patients taking multiple medications that typically use the CYP3A4 pathway.

Pitavastatin's General Purpose

Pitavastatin's general purpose is to improve the patient's blood lipid profile by addressing conditions such as primary hypercholesterolemia. Pitavastatin functions by competitively inhibiting the enzyme HMG-CoA reductase in the liver, which significantly reduces the body's internal manufacture of cholesterol. This action leads to a potent reduction in low-density lipoprotein cholesterol (LDL-C) and total cholesterol, while also promoting a consistent increase in high-density lipoprotein cholesterol (HDL-C). This mechanism provides a comprehensive strategy for managing lipid imbalances, making it a recognized choice for patients needing effective management of elevated LDL-C levels.

Regulatory References

What side effects are possible with Livazo?

Official Adverse Reactions and Safety Information

Livazo (Pitavastatin) is associated with adverse reactions that are classified by frequency according to government regulatory standards. The medicine's safety profile is defined by effects categorized into System-Organ Classes (SOC), with particular emphasis on musculoskeletal and hepatobiliary risks.

Frequency Classification

The following effects are listed in official labeling:

Classification	Examples of Documented Adverse Reactions
Common	Myalgia (muscle pain), Back pain, Diarrhea, Constipation, Headache
Rare	Rhabdomyolysis, Gynaecomastia
Not Known	Immune-Mediated Necrotizing Myopathy (IMNM), Hepatic failure, Angioedema

Serious Safety Concerns

Regulatory documents highlight rare but clinically important reactions. These serious adverse reactions include Rhabdomyolysis, which involves severe muscle breakdown and potential renal (kidney) failure, and rare reports of Hepatic Failure. The potential for Immune-Mediated Necrotizing Myopathy (IMNM), a chronic muscle condition, is also documented.

Safety Restrictions and Contraindications

Livazo is subject to specific safety restrictions defined in official labeling. It is contraindicated (absolutely forbidden for use) during pregnancy and lactation and for patients with active liver disease or severe hepatic impairment. Co-administration with the drug Cyclosporine is also strictly forbidden due to a significantly increased risk of severe muscle damage. Caution is advised, and monitoring may be required, for older adults and individuals with pre-existing renal impairment, who may have an increased risk of myopathy.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory profile for Livazo (Pitavastatin) overdosage is centered on the risk of exaggerating known serious adverse effects, primarily involving muscle and liver function. Experience with overdosage is limited, and there is no specific antidote known for Pitavastatin.

Overdose or excessive exposure is linked to an increased risk of severe myopathy (muscle pain, weakness, or tenderness) and its life-threatening complication, rhabdomyolysis, which can lead to acute kidney injury. Other serious outcomes reported include fatal and non-fatal hepatic failure.

Documented Manifestation	Action Mandated by Regulator
Unexplained Muscle Symptoms, Markedly Elevated CK	Discontinue Pitavastatin immediately.
Collapse, Seizure, Trouble Breathing, Unconsciousness	Call emergency services (e.g., 911) immediately.

Official guidance requires patients to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. If overdosage occurs, management must be symptomatic and supportive. Due to the drug's high protein binding, hemodialysis is not expected to be beneficial.

Therapeutic Uses of Livazo

What Livazo Treats: Main Uses and Benefits

Livazo (Pitavastatin) is used to address the systemic imbalance stemming from high levels of lipids in the blood, a condition known as hyperlipidemia. This therapeutic approach is considered relevant for easing the physiological strain caused by chronic lipid levels. This medication is applied as an adjunct to diet and lifestyle changes to help with the reduction of elevated levels of LDL-C (low-density lipoprotein or "bad" cholesterol) and to help with the increase in HDL-C (high-density lipoprotein or "good" cholesterol) in adults.

It is primarily used for managing primary hypercholesterolemia, mixed dyslipidemia, and the high-risk genetic disorder Heterozygous Familial Hypercholesterolemia (HeFH) in eligible adults and pediatric patients. A key therapeutic benefit of using Livazo involves addressing the patient's long-term cardiovascular risk, playing a role in the management of a reduction in the probability of serious vascular events such as a heart attack or stroke over time.

This approach supports the body's cardiovascular stability and management of long-term risk.

Quick Fact: Relief for Atherogenic Lipid Profile Livazo helps address lipid imbalances that appear in the form of elevated blood fat markers. It is used across conditions presenting with systemic concerns in laboratory results, supporting the patient by contributing to a healthier lipid profile and easing the overall physiological load.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Livazo (Pitavastatin) eligibility is defined by regulatory authorities based on specific health conditions, reproductive status, and age. The medicine is contraindicated (must not be used) in several specific patient groups.

Contraindications (Must Not Use)

Livazo is contraindicated for patients with:

Active Liver Disease, including acute liver failure or decompensated cirrhosis, or unexplained persistent elevations of hepatic transaminase levels.
Co-administration with Cyclosporine (an immunosuppressant).
Known hypersensitivity to pitavastatin or any component of the product.
Pregnancy or in women who may become pregnant, and nursing mothers (breastfeeding).

Conditional and Age-Based Use

Population Group	Eligibility Status
Adults	Approved for use in adults.
Pediatrics	Use is established only for children 8 years and older with Heterozygous Familial Hypercholesterolemia (HeFH); it is not established for those younger than 8.
Renal Impairment	Use requires caution. Patients with severe renal impairment have a lower maximum allowed dose.
Myopathy Risk	Caution is advised in patients with predisposing factors for myopathy, such as advanced age (ge 65 years) or inadequately treated hypothyroidism.

What should I know about interactions with other medicines?

Livazo (pitavastatin) can interact with certain other medicines, which may increase the risk of serious side effects, such as myopathy (muscle pain, tenderness, or weakness) and rhabdomyolysis (severe muscle breakdown).

️ Medications to Use with Caution or Avoid

It is crucial to inform your healthcare provider about all prescription, over-the-counter drugs, and herbal supplements you are taking. The following table highlights key interactions:

Interacting Medicine	Risk/Interaction Summary
Cyclosporine	Contraindicated (must not be used together) due to significant increase in Livazo blood levels and risk of muscle damage.
Gemfibrozil	Concomitant use should be avoided as it greatly increases the risk of myopathy and rhabdomyolysis.
Other Fibrates (e.g., Fenofibrate)	Increased risk of muscle problems. Use requires careful monitoring and risk/benefit assessment.
Niacin (ge 1 g/day)	High doses increase the risk of myopathy and rhabdomyolysis.
Colchicine	Increased risk of myopathy and rhabdomyolysis; use requires careful consideration.
Erythromycin	Increases Livazo blood levels. Livazo dose is typically limited to 1 mg daily.
Rifampin	Increases peak Livazo blood levels. Livazo dose is typically limited to 2 mg daily.

Other Considerations

Unlike many other statins, Livazo's metabolism has a reduced dependence on the CYP450 enzyme system, leading to fewer interactions with some commonly prescribed medications like certain protease inhibitors, warfarin, and digoxin. However, alcohol abuse or a history of significant consumption may also increase the risk of liver problems when taking Livazo.

Mechanism of Action

Targeted Blockade of Cholesterol Production

The core mechanism of Pitavastatin begins in the liver, where it acts as a competitive inhibitor of the enzyme HMG-CoA Reductase. This action directly blocks the rate-limiting step in the mevalonate pathway, limiting the liver's ability to synthesize new cholesterol.

Enhanced Systemic Lipoprotein Clearance

The resulting depletion of the internal cholesterol pool triggers a compensatory response: the liver cells significantly increase the surface expression of LDL Receptors. These newly upregulated receptors enhance the extraction and catabolism of LDL-C and other Apo B-containing lipoproteins directly from the bloodstream, resulting in a net reduction in circulating lipid levels.

Modulation of Vascular Function (Pleiotropic Effects)

Beyond its lipid-lowering capabilities, Pitavastatin also modulates pathways in the blood vessel walls, which contributes to its physiological effect profile. By interfering with specific molecular intermediates, the drug modulates the function of the cells lining the vessels (endothelium) and influences the local bioavailability of nitric oxide, affecting processes of inflammation and oxidative stress within the arterial wall.

Dosage and Administration Information

Official Administration Guidelines

Livazo (Pitavastatin) is a prescription medicine formulated as 1 mg, 2 mg, and 4 mg film-coated tablets for oral use only. The instructions for its use are established by medical guidelines and are intended to be followed precisely.

Standard Administration Rules

The medication is taken once daily. Although it can be consumed with or without food, it is recommended to take the tablet at the same time each day for consistency. The tablets should be swallowed whole with water. If a dose is missed, it should not be doubled to compensate, and the next dose should be taken at the correct, scheduled time.

Usage Parameter	General Adult Regimen
Starting Dose	1 mg or 2 mg once daily
Maximum Dose	4 mg once daily
Titration Interval	Dosage changes typically occur at intervals of 4 weeks or more

Population-Specific Dosing Constraints

Dosage modifications apply to certain patient groups. For adults with moderate or severe renal impairment or those on hemodialysis, the recommended starting dose is 1 mg once daily, and the maximum is limited to 2 mg once daily. Similarly, for patients with mild to moderate hepatic impairment, the maximum daily dose is 2 mg. Specific maximum dose constraints also apply when Livazo is co-administered with certain medications, such as Rifampin (max 2 mg daily) or Erythromycin (max 1 mg daily).

Recent Clinical Evidence

Research evidence / Overview of Studies for Livazo (Pitavastatin)

The main body of evidence relevant to Livazo was gathered in multiple types of studies, primarily short-term Randomized Controlled Trials (RCTs) and very large, long-term observational studies. RCTs were conducted to explore changes measured in cholesterol and other lipid markers with the administration of Pitavastatin. These markers are surrogate endpoints (measurements that stand in for hard clinical outcomes). These trials tracked specific shifts in blood markers, such as Low-Density Lipoprotein Cholesterol (LDL-C), Total Cholesterol, and High-Density Lipoprotein Cholesterol (HDL-C) over defined time intervals.

Findings from these short-term trials described patterns observed in the studies, including shifts toward lower measured LDL-C and Total Cholesterol values and higher measured HDL-C values. For long-term clinical context, research also examined whether the measured changes in lipid markers were associated with Major Adverse Cardiovascular Events (MACE), like heart attack or stroke. Studies focusing on outcomes related to physiological strain or stress and MACE were primarily assessed in large post-marketing surveillance studies that observed responses over years.

Evidence for Use in Specific Genetic Conditions (Familial Hypercholesterolemia)

Livazo was also evaluated in research contexts involving individuals diagnosed with Heterozygous Familial Hypercholesterolemia (HeFH), a condition studied for its association with high cholesterol. This research included dedicated, short-term Randomized Controlled Trials that assessed changes in LDL-C and Total Cholesterol in specific pediatric patients aged 8 to 17, as well as adults with the condition. Trials reported shifts toward lower measured values for key cholesterol markers in these specific populations during the observation period. Studies monitored parameters such as physical growth and sexual maturation alongside the tracking of lipid changes.

Limitations and Areas of Ongoing Research

The most significant limitation is that while data show patterns related to short-term changes in cholesterol, the long-term clinical outcomes (MACE) were historically derived from large observational studies, which are subject to different limitations inherent to their design. Therefore, there is limited information for long-term outcomes that applies universally across all populations, and research is ongoing to further characterize these long-term clinical event rates. Results apply only to the populations studied, and the consistency of long-term effects remains an active area of research.

Key Studies & References

How should Livazo be stored and disposed of?

Storage and Disposal of Livazo (Pitavastatin)

Livazo tablets must be stored under specific environmental and temperature controls as defined by regulatory labeling.

Official Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F). Do not store above 25 C and keep from freezing.
Protection	Keep the medicine protected from light, moisture, and excess heat.
Container	Store in the container it came in, keeping it tightly closed in the outer carton.
Child Safety	Mandatory to keep Livazo out of the sight and reach of children.

Disposal Mandates

Unused or expired Livazo must be disposed of according to local requirements. It is officially stated that the medicine must not be thrown away via wastewater or household trash, as measures are required to help protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.